From: Aptamers: a novel targeted theranostic platform for pancreatic ductal adenocarcinoma
Name | Target | SELEX method | Positive selection | Negative selection | Oligos | Applications | Model | Ref. |
---|---|---|---|---|---|---|---|---|
M9–5 | Cyclophilin B | Secretome | MiaPaCa-2 | HPDE | RNA | biomarker detection | Patients and | [45] |
KPC mice serum | [44] | |||||||
C14B | AGR2 | Protein | AGR2-GST | GST | DNA | probe generation | In vitro | [68] |
SQ-2 | ALPPL-2 | Cell | Panc-1 | HPDE | RNA | biomarker detection | In vitro | [38] |
Capan-1 | biosensor generation | [39] | ||||||
BC-15 | hnRNP A1 | Tissue | PDAC | Adjacent normal tissue | DNA | CTCs detection | Patients serum | [46] |
XQ-2d | CD71 | Cell | PL45 | hTERT-HPNE | DNA | biomarker detection | In vitro | [40] |
Cy-5-labeled fluorescence imaging | Xenograft model Human sections | [93] | ||||||
PL8 | HPAC | Cell | PL45 | TOV-21G | DNA | New biomarker detection | In vitro | [41] |
Apt.1 | CSCs | Cell | HPAC (CRL2119) | HPDE | DNA | CSCs detection; | In vitro | [42] |
Apt.146 | CSCs | Cell | HPAC (CRL2119) | HPDE | DNA | New biomarker detection | In vitro | [42] |
Ap52 | MAGE-A3 | Peptide | MAGE-A3111–125 | None | DNA | Cy-3-labeled fluorescence imaging | In vitro | [49] |
P19/P1 | HPAC | Cell | PANC-1 | Huh7 | RNA | Cy-3-labeled fluorescence imaging | Human tumor tissue sections | [55] |
AP1153 | CCKBR | Peptides | CCKBR peptides | COS-1 | DNA | ICG labeled fluorescence imaging | Orthotopic model | [94] |
Cell | PANC-1 | |||||||
M17 | MMP14 | Cell | 293 T-MMP14 cells | 293 T cells | DNA | Cy-3-labeled fluorescence imaging | Xenograft model | [51] |